303 related articles for article (PubMed ID: 30570529)
21. M-PAST score is better than MAST score for the diagnosis of active fibrotic nonalcoholic steatohepatitis.
Imajo K; Saigusa Y; Kobayashi T; Nagai K; Nishida S; Kawamura N; Doi H; Iwaki M; Nogami A; Honda Y; Kessoku T; Ogawa Y; Kirikoshi H; Yasuda S; Toyoda H; Hayashi H; Kokubu S; Utsunomiya D; Takahashi H; Aishima S; Kim BK; Tamaki N; Saito S; Yoneda M; Loomba R; Nakajima A
Hepatol Res; 2023 Sep; 53(9):844-856. PubMed ID: 37237426
[TBL] [Abstract][Full Text] [Related]
22. Vibration Controlled Transient Elastography in Screening for Silent Liver Diseases.
Said E; Abdel-Gawad M; Abdelsameea E; Elshemy EE; Abdeen N; Elbasiony M; Omran D; Elesnawy Y; Eid A; Lashen SA; Elbahr O; Naguib GG; Afify S; Bahbah EI; Alboraie M
Eur J Gastroenterol Hepatol; 2023 Oct; 35(10):1204-1210. PubMed ID: 37577784
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of Quantitative Imaging Biomarkers for Early-phase Clinical Trials of Steatohepatitis in Adolescents.
Goyal NP; Sawh MC; Ugalde-Nicalo P; Angeles JE; Proudfoot JA; Newton KP; Middleton MS; Sirlin CB; Schwimmer JB
J Pediatr Gastroenterol Nutr; 2020 Jan; 70(1):99-105. PubMed ID: 31633654
[TBL] [Abstract][Full Text] [Related]
24. Validation of the Blood Test MACK-3 for the Noninvasive Diagnosis of Fibrotic Nonalcoholic Steatohepatitis: An International Study With 1924 Patients.
Canivet CM; Zheng MH; Qadri S; Vonghia L; Chuah KH; Costentin C; George J; Armandi A; Adams LA; Lange NF; Blanchet O; Moal V; Younes R; Roux M; Chan WK; Sturm N; Eslam M; Bugianesi E; Wang Z; Dufour JF; Francque S; Yki-Järvinen H; Zheng KI; Boursier J
Clin Gastroenterol Hepatol; 2023 Nov; 21(12):3097-3106.e10. PubMed ID: 37031715
[TBL] [Abstract][Full Text] [Related]
25. Repeatability of MRI Biomarkers in Nonalcoholic Fatty Liver Disease: The NIMBLE Consortium.
Fowler KJ; Venkatesh SK; Obuchowski N; Middleton MS; Chen J; Pepin K; Magnuson J; Brown KJ; Batakis D; Henderson WC; Shankar SS; Kamphaus TN; Pasek A; Calle RA; Sanyal AJ; Loomba R; Ehman R; Samir AE; Sirlin CB; Sherlock SP
Radiology; 2023 Oct; 309(1):e231092. PubMed ID: 37815451
[TBL] [Abstract][Full Text] [Related]
26. The Steatosis-Associated Fibrosis Estimator (SAFE) score for assessing significant liver fibrosis in patients with psoriasis.
Chularojanamontri L; Panjapakkul W; Paringkarn T; Hutachoke T; Chaiyabutr C; Silpa-Archa N; Wongpraparut C; Bandidniyamanon W; Charatcharoenwitthaya P
Clin Exp Dermatol; 2024 Mar; 49(4):337-343. PubMed ID: 37956400
[TBL] [Abstract][Full Text] [Related]
27. Controlled attenuation parameter accurately detects liver steatosis in people with HIV.
Duarte M; Tien P; Ma Y; Noworolski SM; Korn N; Price JC
AIDS; 2022 Dec; 36(15):2147-2152. PubMed ID: 35950941
[TBL] [Abstract][Full Text] [Related]
28. A Novel Score Based on Controlled Attenuation Parameter Accurately Predicts Hepatic Steatosis in Individuals With Metabolic Dysfunction Associated Steatotic Liver Disease: A Derivation and Independent Validation Study.
An ZM; Liu QH; Ye XJ; Zhang Q; Pei HF; Xin X; Yuan J; Huang Q; Liu K; Lu F; Yan ZH; Zhao Y; Hu YY; Zheng MH; Feng Q
Clin Transl Gastroenterol; 2024 Mar; 15(3):e00680. PubMed ID: 38240390
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic Performance of Quantitative Ultrasound Parameters in Non-alcoholic Fatty Liver Disease.
Torkzaban M; Wessner CE; Halegoua-DeMarzio D; Lyshchik A; Nam K
Acad Radiol; 2024 Jan; 31(1):199-211. PubMed ID: 37507328
[TBL] [Abstract][Full Text] [Related]
30. FAST and Agile-the MASLD drift: Validation of Agile 3+, Agile 4 and FAST scores in 246 biopsy-proven NAFLD patients meeting MASLD criteria of prevalent caucasian origin.
Taru MG; Tefas C; Neamti L; Minciuna I; Taru V; Maniu A; Rusu I; Petrushev B; Procopciuc LM; Leucuta DC; Procopet B; Ferri S; Lupsor-Platon M; Stefanescu H
PLoS One; 2024; 19(5):e0303971. PubMed ID: 38781158
[TBL] [Abstract][Full Text] [Related]
31. Fibroscan-Aspartate Aminotransferase Score Predicts Liver-Related Outcomes, but Not Extrahepatic Events, in a Multicenter Cohort of People With Human Immunodeficiency Virus.
Sebastiani G; Milic J; Kablawi D; Gioè C; Al Hinai AS; Lebouché B; Tsochatzis E; Finkel J; Ballesteros LR; Ramanakumar AV; Bhagani S; Benmassaoud A; Mazzola G; Cascio A; Guaraldi G
Clin Infect Dis; 2023 Aug; 77(3):396-404. PubMed ID: 37013396
[TBL] [Abstract][Full Text] [Related]
32. Nonalcoholic Fatty Liver Disease, Liver Fibrosis, and Utility of Noninvasive Scores in Patients With Acromegaly.
Eroğlu İ; Iremli BG; Idilman IS; Yuce D; Lay I; Akata D; Erbas T
J Clin Endocrinol Metab; 2023 Dec; 109(1):e119-e129. PubMed ID: 37590020
[TBL] [Abstract][Full Text] [Related]
33. Human Immunodeficiency Virus Is Associated With Elevated FibroScan-Aspartate Aminotransferase (FAST) Score.
Price JC; Ma Y; Kuniholm MH; Adimora AA; Fischl M; French AL; Golub ET; Konkle-Parker D; Minkoff H; Ofotokun I; Plankey M; Sharma A; Tien PC
Clin Infect Dis; 2022 Dec; 75(12):2119-2127. PubMed ID: 35511608
[TBL] [Abstract][Full Text] [Related]
34. Case-control analysis of venous thromboembolism risk in non-alcoholic steatohepatitis diagnosed by transient elastography.
Suresh MG; Gogtay M; Singh Y; Yadukumar L; Mishra AK; Abraham GM
World J Clin Cases; 2023 Dec; 11(34):8126-8138. PubMed ID: 38130793
[TBL] [Abstract][Full Text] [Related]
35. Role of Alanine Transaminase and Transient Elastography in Categorising Nonalcoholic Fatty Liver Disease Subgroups.
Shabbir A; Abbas Z; Khatoon A; Mirza T
J Coll Physicians Surg Pak; 2024 Jan; 34(1):22-26. PubMed ID: 38185955
[TBL] [Abstract][Full Text] [Related]
36. Low liver fat in non-alcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality.
Lee SW; Huang DQ; Bettencourt R; Ajmera V; Tincopa M; Noureddin N; Amangurbanova M; Siddiqi H; Madamba E; Majzoub AM; Nayfeh T; Tamaki N; Izumi N; Nakajima A; Yoneda M; Idilman R; Gumussoy M; Oz DK; Erden A; Loomba R
Aliment Pharmacol Ther; 2024 Jan; 59(1):80-88. PubMed ID: 37968251
[TBL] [Abstract][Full Text] [Related]
37. Validity of fatty liver prediction scores for diagnosis of fatty liver by Fibroscan.
Jeong S; Park SJ; Na SK; Park SM; Song BC; Oh YH
Hepatobiliary Pancreat Dis Int; 2024 Aug; 23(4):353-360. PubMed ID: 36870896
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis.
Sanyal AJ; Shankar SS; Yates KP; Bolognese J; Daly E; Dehn CA; Neuschwander-Tetri B; Kowdley K; Vuppalanchi R; Behling C; Tonascia J; Samir A; Sirlin C; Sherlock SP; Fowler K; Heymann H; Kamphaus TN; Loomba R; Calle RA
Nat Med; 2023 Oct; 29(10):2656-2664. PubMed ID: 37679433
[TBL] [Abstract][Full Text] [Related]
39. Roles of Radiological Tests in Clinical Trials and the Clinical Management of Nonalcoholic Fatty Liver Disease.
Dunn W; Castera L; Loomba R
Clin Liver Dis; 2023 May; 27(2):363-372. PubMed ID: 37024213
[TBL] [Abstract][Full Text] [Related]
40. Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan.
Tuong TTK; Tran DK; Phu PQT; Hong TND; Dinh TC; Chu DT
Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32183383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
